Related Experiment Video
Updated: Aug 18, 2025

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Sex-related differences in premature cardiovascular disease in familial hypercholesterolemia
Anandita Agarwala1, Elena Deych2, Laney K Jones3
1Center for Cardiovascular Disease Prevention, Cardiovascular Division, Baylor Scott and White Health Heart Hospital Baylor Plano, Plano, TX, USA.
Insights
Familial hypercholesterolemia (FH) significantly increases premature atherosclerotic cardiovascular disease (ASCVD) risk in both men and women. Women with premature ASCVD had higher cholesterol levels, indicating a need for aggressive treatment strategies in FH patients.
Area of Science:
- Cardiology
- Genetics
- Public Health
Background:
- Familial hypercholesterolemia (FH) is linked to increased premature atherosclerotic cardiovascular disease (ASCVD).
- Limited data exists on sex-specific differences in premature ASCVD and associated risk factors within the FH population.
Purpose of the Study:
- To evaluate the prevalence and risk factors of premature ASCVD in men and women with FH.
- To assess sex-specific differences in ASCVD burden and lipid treatment outcomes among FH patients.
Main Methods:
- Retrospective analysis of 782 individuals with confirmed FH across 5 U.S. clinics.
- Sex-stratified analysis using generalized linear models to identify predictors of premature ASCVD and lipid treatment outcomes.
- Covariates included age, sex, diabetes mellitus, hypertension, and smoking status.
Main Results:
- Premature ASCVD was observed in 35% of men and 18% of women with FH.
- Women with premature ASCVD exhibited higher mean treated total cholesterol and LDL-C levels compared to men.
- Analysis identified key predictors for premature ASCVD and treatment outcomes.
Conclusions:
- High rates of premature ASCVD affect both sexes in FH populations.
- FH may reduce the typical sex-based disparities in the onset of premature ASCVD.
- Aggressive prevention and treatment, including addressing non-lipid risk factors and residual hypercholesterolemia, are crucial for FH patients, especially women.
Background:
Familial hypercholesterolemia (FH) is associated with an increased prevalence of premature atherosclerotic cardiovascular disease (ASCVD), however, little is known about sex-specific differences in premature ASCVD and its risk factors.
Objective:
The present study seeks to assess the burden and risk factors for premature ASCVD among men and women with FH.
Methods:
In this study we retrospectively examined sex-specific differences in ASCVD prevalence, risk factor burdens, and lipid treatment outcomes in 782 individuals with clinically or genetically confirmed FH treated in 5 U.S. lipid and genetics clinics. A generalized linear model using Binomial distribution with random study site effect and sex-stratified analysis was used to determine the strongest predictors of premature ASCVD, and lipid treatment outcomes. Covariates included age, sex, diabetes mellitus (DM), hypertension, and current smoking.
Results:
Among the cohort, 98/280 men (35%) and 89/502 women (18%) had premature ASCVD (defined as <55 years in men and <65 years in women). Women with premature ASCVD had higher mean treated total cholesterol (216 vs. 179 mg/dl, p=<0.001) and LDL-C (135 vs. 109 mg/dl, p= 0.005).
Conclusion:
These data confirm that high percentages of women and men with FH develop premature ASCVD, and suggest that FH may narrow the observed sex difference in premature ASCVD onset. These data support more aggressive prevention and treatment strategies in FH, including in women, to reduce non-lipid risk factors and residual hypercholesterolemia.
Related Concept Videos
Coronary Artery Disease I: Introduction
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Cholesterol: Significance and Regulation
Considering cholesterol and...
Coronary Artery Disease II: Pathophysiology
Sex-linked Disorders

